First-episode psychosis intervention programme versus standard care for the clinical management of early phases of psychosis: cost analysis.

Background: Early intervention programmes (EIPs) in psychosis have gained attention as specialised interventions to improve health-related and societal impacts for people with psychotic disorders. Previous studies have presented evidence in favour of EIPs over the first year of intervention, despite none considering the critical period before psychosis onset (5 years).

Aims: To compare the associated costs of the First Episode Psychosis Intervention Program (CRUPEP) and treatment as usual (TAU) in a real-world cohort in a non-specialised psychiatric community setting.

Violence in first-episode psychosis: evidence from an early intervention in psychosis programme.

Background: Psychotic disorders are frequently associated with a public perception of dangerousness and belligerence. This situation has contributed to the social stigmatisation of people with severe mental illness and the resulting discrimination that this scenario entails. Despite efforts to demystify such disorders, the association between violent behaviour and psychosis remains unclear.

Clinical Management and Assessment of the Early Stages of Psychosis: A Multidimensional Approach.

Early intervention in psychosis has emerged as an integrated clinical and research strategy for the comprehensive care of people presenting with a first psychotic episode (FEP). In this sense, a multidisciplinary approach is essential for early detection and assessment of preliminary stages of the illness. The main objectives of early intervention programs include the implementation of specialized interventions aimed at promoting functional recovery and improving quality of life.

Neuropsychological and Functional Assessment of Cognitive Impairments in Schizophrenia.

Cognitive deficits are a central feature of psychotic disorders. Their impact and relevance for clinical prognosis and functional recovery, together with their usefulness in the development of novel therapeutic targets, have emphasized the role of cognition in the diagnosis and therapeutic management of schizophrenia. Here we describe the main aspects to consider before, during, and after the neuropsychological assessment of main cognitive domains affected in schizophrenia, from a research perspective toward clinical practice.

Isolation and Differentiation of Neurons and Glial Cells from Olfactory Epithelium in Living Subjects.

The study of psychiatric and neurological diseases requires the substrate in which the disorders occur, that is, the nervous tissue. Currently, several types of human bio-specimens are being used for research, including postmortem brains, cerebrospinal fluid, induced pluripotent stem (iPS) cells, and induced neuronal (iN) cells. However, these samples are far from providing a useful predictive, diagnostic, or prognostic biomarker.